Key points
This page provides guidance for testing for bloodborne pathogens and communication tools for notifying patients and the public of potential exposures. CDC staff are always available for consultation to discuss testing algorithms for specific notification settings.

Recommended tests
There may be recommendations for bloodborne pathogen screening as part of the notification process that will depend on the risk of transmission.
Suggested tests may vary according to the recency and likelihood of exposure and typically include the below recommendations.
Hepatitis B testing
For hepatitis B, consider serologic testing for hepatitis B surface antigen (HBsAg), as well as testing for antibody to hepatitis B surface antigen (anti-HBs) and total antibody to hepatitis B core antigen (total anti-HBc) to determine infection and immunity status.
Note: In March 2023, CDC published updated recommendations1 for hepatitis B screening and testing among adults that now include recommendations for one-time hepatitis screening for all adults with a triple panel test (HBsAg, anti-HBs, and total anti-HBc).
Hepatitis C testing
Initiate hepatitis C testing with a hepatitis C virus (HCV) antibody test with reflex to NAT for HCV RNA if the antibody test is positive/reactive. CDC recommends that all samples needed to diagnose hepatitis C be collected in a single visit. For more information on identifying HCV infection, see the HCV recommended testing sequence.
For more information, see clinical screening and testing for hepatitis C.
Notification guidance and toolkits
- Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023. MMWR Recomm Rep 2023;72(No. RR-1):1–25. DOI: http://dx.doi.org/10.15585/mmwr.rr7201a1.